🟢 Corcept Therapeutics is trading 4.16% up today amid broader biotech strength

Corcept Therapeutics is trading 4.16% up at $118.49, supported primarily by broader biotechnology strength rather than a newly announced company-specific catalyst.

• The biotech sector is up 2.07% during the regular session, while the Nasdaq is up 0.32%.
• The September 18 CHMP recommendation for Lifyorli remains a favorable recent backdrop.
• Available evidence does not establish it as the direct cause of September 22’s move.